## Effective connectivity of emotion and cognition under psilocybin

| 3<br>4<br>5<br>6<br>7<br>8<br>9<br>10<br>11 | Devon Stoliker <sup>1,2*</sup> , Leonardo Novelli <sup>1,2</sup> , Franz X. Vollenweider <sup>3</sup> , Gary F. Egan <sup>1,2</sup> , Katrin H. Preller <sup>3+</sup> ,<br>Adeel Razi <sup>1,2,4,5+</sup><br><sup>1</sup> Turner Institute for Brain and Mental Health, Monash University, Clayton, VIC<br><sup>2</sup> Monash Biomedical Imaging, Monash University, Clayton, VIC<br><sup>3</sup> Department of Psychiatry, Psychotherapy & Psychosomatics, Psychiatric University Hospital Zurich,<br>Zurich, Switzerland<br><sup>4</sup> Wellcome Centre for Human Neuroimaging, UCL, London, United Kingdom<br><sup>5</sup> CIFAR Azrieli Global Scholars Program, CIFAR, Toronto, Canada |
|---|---|
| 12  | + Joint Senior Authors  |
| 13  |   |
| 14  | Abstract  |
| 15  |   |
| 16  | Classic psychedelics alter sense of self and patterns of self-related thought. These changes are  |
| 17  | hypothesised to underlie their therapeutic efficacy across internalising pathologies such as addiction and  |
| 18  | depression. Using resting-state functional MRI images from a randomised, double blinded, placebo-   |
| 19  | controlled clinical trial of 24 healthy adults under 0.215mg/kg psilocybin, we investigated how psilocybin  |
| 20  | modulates the effective connectivity between resting state networks and the amygdala that are involved in   |
| 21  | the appraisal and regulation of emotion and association with clinical symptoms. The networks included   |
| 22  | the default mode network (DMN), salience network (SN) and central executive network (CEN).  |
| 23  | Psilocybin decreased top-down effective connectivity from the resting state networks to the amygdala and  |
| 24  | decreased effective connectivity within the DMN and SN, while the within CEN effective connectivity   |
| 25  | increased. Effective connectivity changes were also associated with altered emotion and meaning under   |
| 26  | psilocybin. Our findings identify changes to cognitive-emotional connectivity associated with the   |
| 27  | subjective effects of psilocybin and the attenuation of the amygdala signal as a potential biomarker of   |
| 28  | psilocybin's therapeutic efficacy.  |
| 29  |   |

Keywords – fMRI, psychedelics, resting state connectivity, dynamic causal modelling, psilocybin,
emotion, cognition, amygdala

32

#### 33 Introduction

34

35 Psilocybin, the main active compound of so-called magic mushrooms, is a serotonergic psychedelic that 36 has been used throughout history in religious and medical rituals to alter consciousness (Carod-Artal, 37 2015; Nichols, 2016). It belongs to a larger group of substances such as ayahuasca (DMT) and mescaline 38 that share molecular binding kinetics to serotonergic 5-HT receptors distributed throughout the brain 39 (Nichols, 2012). Agonism of the 5-HT2A receptor is primarily responsible for psychedelic subjective 40 effects that can cause powerful changes to subjective experience (Vollenweider et al 1998; (Kometer et 41 al., 2012) Kometer et al. 2013; Preller et al. 2017; Kraehenmann et al. 2017). Psychedelics can also 42 produce feelings of subjective wellbeing (Hirschfeld & Schmidt, 2020) and profound changes in self-43 awareness and perception, including visual hallucinations and synaesthesia, and a sense of transcendence 44 of time and space (Studerus, Gamma, & Vollenweider, 2010; Swanson, 2018; Wittmann et al., 2007; 45 (Stoliker, Egan, Friston, & Razi, 2022). Altered (self-)perception and self-awareness are unique effects of 46 serotonergic psychedelics and may involve an experience of ego dissolution, defined as a loss of self-47 boundaries and sense of unity between the self and the environment (Stoliker, Egan, Friston, & Razi, 48 2021; Stoliker, Egan, Friston, et al., 2022)Lebedev et al., 2015). Although complete ego dissolution is 49 rare at the medium dose potency used in clinical trials, several studies have found that overall blissful ego 50 dissolution (as measured by the total mystical score or oceanic self-boundlessness) is associated with 51 better long-term outcomes in healthy subjects (Griffiths et al., 2011) and reduced symptoms of depression 52 (Griffiths et al., 2016; Roseman, Nutt, & Carhart-Harris, 2018; Ross et al., 2016) and addiction 53 (Bogenschutz et al., 2015; Garcia-Romeu, Griffiths, & Johnson, 2014). 54

56 Depression has been linked to a fundamental sense of disconnectedness (Northoff, 2007), which may be 57 ameliorated by psychedelics. Studies have found reduced depression scores and improved wellness 58 associated with enhanced the subjective sense of connectedness following an acute psychedelic 59 experience (R. L. Carhart-Harris et al., 2018; Watts, Day, Krzanowski, Nutt, & Carhart-Harris, 2017; 60 Watts et al., 2022). Research findings indicate a strong correlation between ratings of psychological 61 insight one day after a session with psilocybin and decreases in depression four weeks later (Alan K. 62 Davis et al., 2021). Reduced depression may also be mediated by increased cognitive and psychological 63 flexibility after psychedelics (A. K. Davis, Barrett, & Griffiths, 2020; Doss et al., 2021). These findings 64 suggest that the long-term benefits of psychedelics for mental health may result from modulation of the 65 regulation of emotions and cognitive processing (Duerler, Vollenweider, & Preller, 2022; Franz X. 66 Vollenweider & Preller, 2020). Moreover, the acute psychedelic experience appears to be crucial to these 67 changes.

68

69 The amygdala is a bilateral subcortical region composed of many subnuclei that integrate cortical and 70 thalamic sensory inputs (Babaev, Piletti Chatain, & Krueger-Burg, 2018). Its primary function is to 71 respond to the emotional significance of stimuli and regulate arousal (Alexander et al., 2021; Bonnet et 72 al., 2015). For example, presentations of positive or negative emotional stimuli, such as physical threats, 73 elicit activation of the amygdala (Alexander et al., 2021; Garavan, Pendergrass, Ross, Stein, & Risinger, 74 2001; Hobin, Goosens, & Maren, 2003; Weymar & Schwabe, 2016). The amygdala also responds to 75 cognitive-emotional significance. For example, when personal beliefs are threatened (Kaplan, Gimbel, & 76 Harris, 2016). This demonstrates self-beliefs can condition and regulate amygdala emotional responses. 77 Similarly, complex emotions such as shame are associated with the amygdala and can be diminished by 78 its damage (Piretti et al., 2020). Emotional empathy is also associated with amygdala function (Geng et 79 al., 2018; Hillis, 2014; Marsh et al., 2013), and has been reported to be modified by psilocybin (Pokorny, 80 Preller, Kometer, Dziobek, & Vollenweider, 2017; Preller et al., 2015).

82 Further associations between emotional and behaviour regulation and the amygdala are demonstrated by 83 damage to the amygdala which affects decision-making (Gupta, Koscik, Bechara, & Tranel, 2011) and 84 memory (Adolphs, Tranel, & Denburg, 2000). Amygdala hyperactivation is also a marker of stress and 85 anxiety, which are implicated across internalising disorders for which psychedelics demonstrate efficacy 86 (Nutt & Carhart-Harris, 2020); Koob & Volkow, 2010; Luo, Xue, Shen, & Lu, 2013; Menon, 2011). 87 Emotional regulation depends on top-down and bottom-up modulation of the amygdala (McRae, Misra, 88 Prasad, Pereira, & Gross, 2012; Ochsner et al., 2009) and appears to be altered by psychedelics. For 89 example, healthy adults administered psilocybin show reduced effective connectivity from the amygdala 90 to the primary visual cortex coincident with reduced threat processing (Kraehenmann et al., 2015) 91 (Kraehenmann et al., 2016). The semisynthetic psychedelic drug lysergic diethylamide acid (LSD) has 92 also been shown to dampen the amygdala response to fearful stimuli (Mueller et al., 2017; Barrett, Doss, 93 Sepeda, Pekar, & Griffiths, 2020). Furthermore, decreased amygdala activity has been correlated with 94 positive mood under psilocybin lasting up to one month (Kraehenmann et al., 2015; Barrett et al., 2020). 95 However, subjects with treatment resistant depression imaged one day post-treatment show increased 96 amygdala responses to stimuli with psilocybin as well as improvements in depressive symptoms 97 (Roseman, Demetriou, Wall, Nutt, & Carhart-Harris, 2018; Barrett et al., 2020). Together, these results 98 suggest a change in amygdala connectivity under the acute influence of psychedelics may be a biological 99 mechanism underwriting the beneficial, mood-enhancing effects of psilocybin.

100

The amygdala is integrated with cognition through top-down projections from midline cortical regions (Etkin et al., 2011; Kraehenmann et al., 2016; Robinson et al., 2013). These projections are thought to underlie the perception and intensity of positive and negative emotions (Bonnet et al., 2015) and abnormal connectivity of this circuitry underlies psychopathological conditions such as anxiety disorders (Menon, 2011). Amygdala connectivity changes that involve frontal cortical regions have been found in several studies suggesting psilocybin modulates the top-down control of limbic regions involved in emotional processing (Bernasconi et al., 2014; Mertens et al., 2020; Mueller et al., 2017; Barrett et al., 2020). Changes to the amygdala and cortical regions are sustained well beyond the half-life of psilocybin and may last up
to one month post administration (Barrett, Doss, Sepeda, Pekar, & Griffiths, 2020), demonstrating the
lasting neural changes in association with increased positive affect.

111

Emotion is a flexible, dynamic and functionally integrated with cognitive regions of the brain (Lindquist, Satpute, Wager, Weber, & Barrett, 2016). The function of cortical regions linked to amygdala are related to the sense of self, self-referential cognition, cognitive appraisal, and emotional regulation. For example, limbic-cortical dysregulation has been reported to impact mood regulation (Zeng et al., 2012). The changes to cortical regions under the acute effects of psychedelics may modulate subcortical regions that disrupt affective responses that may potentially support therapeutic responses. Here we investigate to what extent psilocybin modulates the relationship of cognitive-emotional networks

interactions that may be relevant for therapeutic outcomes. We investigated amygdala connectivity to
regions that form frontal and anterior nodes of distinct large-scale resting-state networks (RSNs). RSNs
are determined by temporally correlated activation across spatially distributed brain regions and serve
essential functions in cognition (Fox et al., 2005; Raichle, 2015). The RSN regions of particular relevance
to this study are abundant in 5-HT2A receptors (Saulin, Savli, & Lanzenberger, 2012; R. L. CarhartHarris & Friston, 2019) and include the default mode network (DMN), central executive network (CEN)
and the salience network (SN).

127

The DMN integrates internal and external information to perform self-referential mental activity involved in forming self-beliefs (Amey, Leitner, Liu, & Forbes, 2022; Tompson, Chua, & Kitayama, 2016) and is composed of the medial prefrontal cortex (mPFC) and posterior cingulate cortex (PCC) central hub regions. Increased DMN connectivity with the amygdala is observed in depressed subjects (Sheline Yvette et al., 2009) and has been associated with symptoms such as rumination (Cooney, Joormann, Eugène, Dennis, & Gotlib, 2010). In contrast, decreased coupling of the central hub regions of the DMN 134 was reported in association with the reduced mind wandering of advanced meditation practitioners 135 (Judson A. Brewer et al., 2011). Similar decoupling was found acutely (Carhart -Harris et al 2012) and 136 two days after psilocybin (R. L.; Smigielski, Scheidegger, Kometer, & Vollenweider, 2019). We 137 hypothesise reduced interactions between the amygdala and DMN and reduced within-DMN connectivity 138 may underpin an altered sense of self and self-related emotion under psychedelic subjective effects and 139 these subjective effects can be measured using the blissful state (emotion) and changed meaning of 140 percepts subscales of the 5D-ASC (Studerus, Gamma, & Vollenweider, 2010). Connectivity changes, 141 particularly those associated with subjective changes, may serve as a biomarker of connectivity that may 142 have therapeutic properties.

143

144 The central executive network (CEN) is a RSN involved in thinking, planning, and controlling attention 145 (Andrews-Hanna et al., 2014; Menon, 2011). Abnormal CEN function is associated with mental health in 146 various cognitive disorders. For example, reduced CEN activity has been associated with chronic 147 schizophrenia and depression (Leptourgos et al., 2020; Menon, 2011) and increased CEN-amygdala 148 connectivity was observed in association with catastrophising of chronic pain (Jiang et al., 2016). The 149 central hub regions of the CEN are the dorsolateral prefrontal cortex (dorsolateral PFC) and the lateral 150 posterior parietal cortex (lateral PPC). The dorsolateral PFC serves a primary role in regulating emotion 151 (Underwood et al., 2021) and was associated with worry in healthy adults and individuals with 152 generalised anxiety (Paulesu et al., 2010; Servaas et al., 2014; Jamieson, Harrison, Razi, & Davey, 2022). 153 Under psychedelics, a number of brain mapping studies suggest psychedelics increase the global 154 connectivity and flexibility of CEN connectivity that may be associated with subjective emotional 155 changes (Luppi et al., 2021; Tagliazucchi et al., 2016); Lord et al., 2019). 156 157 The salience network (SN) is a cognitive RSN involved in the detection of salient features in the

158 environment and disengages task-irrelevant activity associated with the DMN, for example during

159 daydreaming. The SN's cardinal regions are the dorsal anterior cingulate cortex (dorsal ACC) and anterior

| 160 | insula (AI). Expanded network compositions of the SN also include the amygdala which may be                  |
|-----|--|
| 161 | important for the initial emotional appraisal of salient stimuli. Overactive salience attributed to          |
| 162 | hyperactivity of the AI or amygdala stimuli is a feature of various forms of psychopathology (Menon,         |
| 163 | 2011) and the AI is important to integrate affective and cognitive signals that influence interoceptive      |
| 164 | responses related to psychosomatic symptoms and anxiety and depression (Paulus, 2006; Terasawa,              |
| 165 | Shibata, Moriguchi, & Umeda, 2013 ;Wiebking et al., 2015). The dorsal ACC region of the SN is                |
| 166 | activated in response to social pain (Rotge et al., 2015) that has been associated with changes in self-     |
| 167 | processing (Smigielski et al. 2019; Smigielski et al., 2020) as well as reduced sense of social exclusion    |
| 168 | under psilocybin (Preller et al., 2016; Preller et al., 2015). Observations under psilocybin have also shown |
| 169 | reduced SN integrity (Lebedev et al., 2015) and changes to effective connectivity from the SN to the         |
| 170 | DMN under LSD (Stoliker, Novelli, et al., 2021). Psychedelics may alter salience functions that select the   |
| 171 | pre-reflective channels of attention and modulate amygdala connectivity involved in emotional attention      |
| 172 | and appraisal (Kapur, 2003; Stoliker, Egan, et al., 2021).   |
| 173 |  |
| 174 | Results:   |
| 175 |  |
| 176 | Network effective connectivity change with the amygdala under psilocybin                                     |
| 177 |  |
| 178 | Participants underwent resting-state fMRI scans 70 minutes post oral administration of psilocybin.           |
| 179 | Effective connectivity between the amygdala and the DMN, SN and CEN and brain-behaviour analysis             |
| 180 | was performed at the group level using the framework of parametric empirical Bayes (PEB, see                 |
| 181 | supplementary material for details). The reported results for effective connectivity and brain-behaviour     |
| 182 | analysis used a threshold of posterior probability $> 0.99$ for inference with very strong evidence. Those   |
| 183 | connections and associations not reported did not exceed this threshold. For more statistical details, see   |
| 184 | Supplementary Table 1.   |

185

- *i) Change of DMN effective connectivity to the amygdala under psilocybin*
- 187 Group level effective connectivity strength between regions of the DMN and amygdala showed decreased
- 188 self-inhibition of the PCC (effect size = -0.21) and decreased effective connectivity from the PCC with
- 189 the left amygdala (effect size = -0.33 Hz) compared to placebo.



190

Fig 1. Default mode network effective connectivity change under psilocybin 70 minutes postadministration. Connections show changes in effective connectivity compared to placebo. Values display effect sizes (posterior expectations) of connections in Hz (except the inhibitory self-connections which are log-scaled). Values linked to subjective effects represent their associations with effective connectivity and represent normalized beta (6) coefficients. All results are for posterior probability > 0.99 (amounting to very strong evidence).

197

```
ii) Change of CEN effective connectivity to the amygdala under psilocybin
```



202 increased self-inhibition of the right dorsolateral PFC (effect size = +0.17), left dorsolateral PFC (effect 203 size = +0.19) and decreased self-inhibition of the left lateral PPC (effect size = -0.2), compared to placebo. 204 Effective connectivity from the left lateral PPC to the left amygdala decreased (effect size = -0.22 Hz) and 205 increased from right lateral PPC to the right dorsolateral PFC (effect size = +0.2 Hz) and decreased to the 206 right amygdala (effect size = -0.39 Hz). Left dorsolateral PFC effective connectivity to the right amygdala 207 decreased (effect size = -0.16 Hz) and increased to the left lateral PPC (effect size = +0.23 Hz), while right 208 dorsolateral PFC increased to the left dorsolateral PFC (effect size = +0.15 Hz) and the right amygdala 209 increased to the left lateral PPC (effect size = +0.28 Hz), compared to placebo.



210

Fig 2. Central executive network effective connectivity change under psilocybin 70 minutes postadministration. Values display effect sizes (posterior expectations) of connections in Hz (except the inhibitory self-connections which are log-scaled). Values linked to subjective effects represent their associations with effective connectivity and represent normalized 8 coefficients. All results are for posterior probability > 0.99.

216

217 *iii)* Change of SN effective connectivity to the amygdala under psilocybin

- 219 Group-level effective connectivity showed analysis showed increased self-inhibition of the right AI
- 220 (effect size = +0.23) and bilateral amygdala (effect size = +0.16 (right) and +0.31 (left)) and decreased
- 221 effective connectivity from the dorsal ACC to right amygdala (effect size = -0.19 Hz) and from left AI to
- the right amygdala (effect size = -0.24 Hz) compared to placebo (Fig 3).
- 223



- 224
- Fig 3. Salience network effective connectivity change under psilocybin 70 minutes post-administration.
  Connections show changes in effective connectivity compared to placebo. Values display effect sizes
  (posterior expectations) of connections in Hz (except the inhibitory self-connections which are log-scaled).
  Values linked to subjective effects represent their associations with effective connectivity and represent
  normalized β coefficients. All results are for posterior probability > 0.99.
- 230

#### 231 Brain-behaviour associations

- *i)* Behavioural associations to DMN-amygdala effective connectivity change under psilocybin
- 233
- 234 The brain-behaviour analysis showed negative association between self-connectivity of PCC and blissful
- state ( $\beta$  coefficient = 0.06), negative association between effective connectivity from PCC to left

| 236 | amygdala and changed meaning of percept ( $\beta$ coefficient = - 0.04), and negative association between           |
|-----|---|
| 237 | effectivity from left amygdala to PCC and changed meaning of percept ( $\beta$ coefficient = - 0.06). See Fig       |
| 238 | 1.  |
| 239 |   |
| 240 | <i>ii)</i> Behavioural associations to CEN-amygdala effective connectivity change under psilocybin                  |
| 241 |   |
| 242 | The brain-behaviour analysis showed positive association between effective connectivity from left lateral           |
| 243 | PPC to right amygdala and blissful state ( $\beta$ coefficient = + 0.03), positive association between effective    |
| 244 | connectivity from right DLPFC to left DLPFC and changed meaning of percept ( $\beta$ coefficient = + 0.03),         |
| 245 | negative association between self-connectivity of left lateral PPC to changed meaning of percept ( $\beta$          |
| 246 | coefficient = - 0.04) ad blissful state ( $\beta$ coefficient = - 0.06), and positive association between effective |
| 247 | connectivity from left DLPFC to left lateral PPC and changed meaning of percept ( $\beta$ coefficient = + 0.07).    |
| 248 | See Fig 2.  |
| 249 |   |
| 250 | <i>iii)</i> Behavioural associations to SN-amygdala effective connectivity change under psilocybin                  |
| 251 |   |
| 252 | The brain-behaviour analysis showed negative association between effective connectivity from left AI to             |
| 253 | right amygdala and changed meaning of percept ( $\beta$ coefficient = - 0.06). See Fig 3.                           |
| 254 |   |
| 255 | Discussion:   |
| 256 |   |
| 257 | To investigate the influence of psilocybin on the interaction between emotion and cognition, we measured            |
| 258 | connectivity changes between the amygdala and selected RSNs. These networks serve functions in                      |
| 259 | selfhood and cognition and are composed of regions linked to the regulation and experience of emotion.              |
| 260 | Our results demonstrate increased inhibitory effective connectivity from cortical regions to the amygdala           |
| 261 | under psilocybin. For example, we showed this change in connectivity from the PCC, left dorsolateral                |

| 262 | PFC, bilateral lateral PPC, dorsal ACC, and left AI. These results suggest cognitive resources do not |
|-----|---|
| 263 | recruit the amygdala under psilocybin, and this modulation of top-down connectivity was related to    |
| 264 | subjective effects of psilocybin.   |

265

266 Examination of the DMN-amygdala connectivity changes under psychedelics did not find effective 267 connectivity change involving the mPFC, which has been frequently cited in association with emotion, 268 such as emotional valence (Willinger et al., 2019; Underwood, Tolmeijer, Wibroe, Peters, & Mason, 269 2021). However, examination of the PCC, which orients information towards the self (Andrews-Hanna, 270 Smallwood, & Spreng, 2014; J. A. Brewer, Garrison, & Whitfield-Gabrieli, 2013; Qin & Northoff, 271 2011), and amygdala revealed connectivity changes and behavioural associations under psilocybin. PCC 272 and amygdala effective connectivity change was bidirectional and accompanied by reduced PCC self-273 inhibition, which indicates increased synaptic gain or its sensitivity to inputs. The increased PCC synaptic 274 gain was associated with the subjective experience of blissful state, and PCC bidirectional inhibition with 275 the left amygdala was associated with changed meaning of percepts. Our findings suggest inhibition 276 between the amygdala and PCC may be an important connectivity change underlying altered meaning 277 (i.e., everyday things gained symbolic, strange, or emotional meaning), that, in turn, may contribute to the 278 change in self-awareness. Our findings also indicate PCC decreased inhibition facilitates blissful feelings. 279 These changes may reflect reduced top-down cognitive control associated with loss of self-referential 280 processing that is experienced as a dissolution of self-boundaries and align with the proposed role of the 281 PCC in self-referential processing (Brewer, Garrison, & Whitfield-Gabrieli, 2013; Qin & Northoff, 2011) 282 as well as previous evidence of PPC change associated to the dissolution of self-boundaries under 283 psychedelics (Muthukumaraswamy et al., 2013). For example, previous findings found PCC self-284 inhibition under LSD, and the PCC's association with diminished self-representation in social interaction, 285 feelings of self and self-other processing under psychedelics (Preller et al., 2017; Preller et al., 2019; 286 Preller et al., 2018; Stoliker, Novelli, et al., 2022).

288 Left dorsolateral PFC and left lateral PPC inhibition to the amygdala was also observed and is situated 289 within the CEN. Connectivity in this network is believed to underlie the evaluative aspect of thought, with 290 the dorsolateral PFC playing a central role in emotional regulation. However, the observed increased top-291 down inhibition of this connectivity to the amygdala was not associated with subjective effects assessed 292 with the 5D-ASC scale. Instead, the pattern of activity in this network is open to interpretation. One 293 characterisation of the observed activity may be its resemblance to hyper-frontality, which is associated 294 with worry and anxiety (Park, Wood, Bondi, Del Arco, & Moghaddam, 2016), and acute psychosis (F. X. 295 Vollenweider et al., 1997). There is also evidence that CEN connectivity is increased, and the amygdala 296 connectivity is decreased, during cognitive control strategies (Herwig et al., 2007; Herwig, Kaffenberger, 297 Jäncke, & Brühl, 2010). However, links between CEN activity and behaviour are suggested to be task and 298 context-dependent (Borders, 2020) and subjects in this study reported nominal anxiety, see Supplementary 299 Material. An alternative interpretation is that the observed connectivity pattern between regions of the CEN 300 constitutes an increase in evaluative thought processes and may be linked to re-appraisal. For example, 301 increased CEN and decreased amygdala activity of healthy adults was observed to increase during emotion-302 introspection, while increased CEN and increased amygdala activity was associated with self-reflection 303 (Herwig et al., 2010). This literature may help explain the activation differences in the amygdala observed 304 between healthy adults under psychedelics and clinical populations in the days after psychedelics. 305 Moreover, increased CEN and decreased amygdala activity align our findings with connectivity underlying 306 emotion-introspection. Although the introspection of healthy adults in this imaging study was not assumed, 307 psilocybin experiences are commonly related to emotional introspection. Further evidence demonstrating 308 the therapeutic capacity of increased intrinsic CEN connectivity is presented in association with resilience 309 (Miller Gregory et al., 2018). Moreover, positive self-appraisal has been associated with increased CEN 310 and amygdala connectivity (Brühl, Rufer, Kaffenberger, Baur, & Herwig, 2014), which may relate to self-311 reflection in the days after psilocybin administration. This evidence indicates the increased CEN 312 connectivity and CEN top-down inhibition to the amygdala as a connectivity change that relates to the 313 therapeutic potential of psilocybin for the revision of beliefs and it warrants further investigation.

314

315 Although we expect re-evaluation of thought under psychedelics to be influenced by the context (i.e., the 316 mindset of participants and environmental setting), measured subjective effects associated with CEN 317 connectivity changes are detectable in the imaging environment. For example, increased connectivity from 318 the left dorsolateral PFC to the left lateral PPC and connectivity between the bilateral dorsolateral PFC was 319 associated with changed meaning of percepts. Moreover, connectivity from the left dorsolateral PFC and 320 right AMG to the left lateral PPC and decreased left lateral PPC self-inhibition were associated with both 321 blissful state and the changed meaning of percepts. The lateral PPC inhibition to the amygdala may suggest 322 its decoupling from the amygdala limits the sensory and interoceptive information to the amygdala, while 323 the left amygdala synaptic gain increased. These results demonstrate nuanced modulation of the CEN-324 amygdala connectivity that align with previous reports of functional desegregation and expanded access to 325 wider dynamics of brain states made available under psychedelics (Atasoy et al., 2017; Barnett, 326 Muthukumaraswamy, Carhart-Harris, & Seth, 2019; R. L. Carhart-Harris & Nutt, 2017; A. K. Davis et al., 327 2020; Matias, Lottem, Dugué, & Mainen, 2017; Stoliker, Egan, & Razi, 2022; Tagliazucchi, Carhart-Harris, 328 Leech, Nutt, & Chialvo, 2014; Watts & Luoma, 2020). These connectivity changes may be important to 329 psilocybin's therapeutic potential that can be targeted to facilitate cognitive-emotional changes.

330

331 The ACC and AI serve essential functions in salience detection, and the integration of these regions with 332 the amygdala may underwrite pathologically enhanced salience detection (Menon, 2011). These regions' 333 inhibition of the right amygdala suggests their role in salience detection is diminished under psilocybin, 334 which may be therapeutic for internalising disorders. Notably, previous literature found that psilocybin 335 acutely reduced mainly the response in the right amygdala to negative stimuli, which may reflect 336 "decentering" from one's emotion and thought that may facilitate reappraisal (Malinowski, 2013). 337 However, inhibited salience detection also aligns with positive symptoms in schizophrenia (i.e., 338 hallucinations and delusions) (Menon, 2011). At higher doses, psychedelics can induce a psychotic-like 339 state in some individuals (F. X. Vollenweider, Vollenweider-Scherpenhuyzen, Babler, Vogel, & Hell,

1998), that may be related to the effect of serotonergic psychedelics on salience detection (Preller et al.,
2017). However, psychotic-like behavioural outcomes rarely occur in a controlled clinical setting (Johnson,
Richards, & Griffiths, 2008; Studerus, Gamma, Kometer, & Vollenweider, 2012; Studerus et al., 2010).

343

344 Previous research shows that increased functional connectivity between the AI and amygdala is associated 345 with relapse of addiction in preclinical studies (Venniro et al., 2017) and behavioural habituation in healthy 346 adults (Denny et al., 2014). Increased effect connectivity of this link has been associated with depression 347 in clinical populations (Kandilarova, Stoyanov, Kostianev, & Specht, 2018). The AI inhibition to the 348 amygdala was associated with changed meaning of percepts that suggests it may be associated with 349 therapeutic behavioural change. Previous task-based research shows reduced dorsal ACC activity in 350 association with blunted response to social exclusion under psilocybin (Preller et al., 2015). Although our 351 findings did not associate subjective effects with this connection, dorsal ACC-related inhibition aligns with 352 the inhibition of social pain (Preller et al., 2016; Preller et al., 2015) and previous findings of this circuit 353 implicate top-down inhibition in the resolution of emotional conflict (Etkin, Egner, Peraza, Kandel, & 354 Hirsch, 2006). DCM also estimated increased self-inhibition in the bilateral amygdala and rAI, suggesting 355 reduced synaptic gain of the regions. LSD produced similar results that demonstrated hypo-connectivity of 356 the right insula (Preller et al., 2018). However, the changes we observed were not associated with the 357 measured psychedelic subjective effects.

358

Taken together, our results suggest that psilocybin attenuates the recruitment of the amygdala. This connectivity contributes to the altered meaning of percepts and subjective emotion. Diminished amygdala activation has been related to emotional regulation (Herwig et al., 2019) and may alter the patterns of connectivity that condition emotional, cognitive and self-reflective responses. Psilocybin induced change to the RSNs that we observed generally aligns with previous literature that shows the increased flexibility and transition of network states under psychedelics, as well as nimble and flexible brain networks are instrumental to positive emotion and affect (Alexander et al., 2021). Therefore, the RSNs reduced 366 connectivity to the amygdala and altered within-RSN effective connectivity that we observed may be 367 important aspects of the subjective effects and emotional-cognitive connectivity changes that therapeutic 368 applications capitalise upon to encourage revision of beliefs.

369

370 Our endeavour to investigate interactions between emotion and cognition in a healthy population under 371 psilocybin has several limitations. For example, our analysis would benefit from MRI scans taken before 372 and after the administration of psilocybin. Exploring links between emotional and associative connectivity 373 also involves deciding network configuration and regions for analysis. Regions such as the ventral striatum, 374 precuneus, and parahippocampus and further subregions of the PFC and ACC may also be valuable for 375 examining the links between emotion and cognition (Underwood et al., 2021). Furthermore, each region 376 selected as part of the network may be determined differently depending on the method of identification of 377 the region. Further standardisation of this process is complex for anatomical reasons and remains under 378 debate. The processing pipeline, participant sample and dose of psilocybin can also strongly impact the 379 reliability of results. Participants were given lower doses than currently used in clinical studies of 380 depression and substance dependence disorders. Therefore, connectivity dynamics may be dissimilar at a 381 higher dose. Data sets at higher doses may provide improved inference and more nuanced characterisation 382 of the neural dynamics of interest. We also overlooked the influence of numerous neurotransmitter systems 383 involved in emotion that may interact with altered serotonin transmission. These interactions may provide 384 a novel line of inquiry to understand psychedelic therapeutic effects.

385

Other limitations in the methods and analysis include the use of global signal regression and the limited temporal resolution. Temporal resolution is likely to be significant in the study of emotion. For example, the time course of emotion may present distinct contributions of brain regions involved in valence and arousal (Alexander et al., 2021). Modalities with temporal specificity capable of resolving insight and emotional change, such as EEG or MEG, which can also be analysed using DCM, are needed in future investigations. Furthermore, studies using task-based fMRI paradigms can induce activations in specific
emotion and cognition related brain regions (Brühl et al., 2014; Herwig et al., 2007; Herwig et al., 2010).

393

394 The generalisability of our results to clinical populations is limited by the use of a small healthy adult 395 sample and the congruence between our results and previous findings. Previous research indicates 396 psychedelics may globally increase bottom-up connectivity (R. Carhart-Harris, Kaelen, & Nutt, 2014; R. 397 L. Carhart-Harris & Friston, 2019; Swanson, 2018). For example, evidence of thalamic connectivity to the 398 cortex supports this view (Müller, Dolder, Schmidt, Liechti, & Borgwardt, 2018; Preller et al., 2019). 399 However, decoupling between limbic regions and the cortex has also been identified (Robin L. Carhart-400 Harris et al., 2016; Lebedev et al., 2015). Our findings that identified increased bottom-up connectivity 401 from the right amygdala to the left lateral PPC align with the latter studies. As psychedelic research 402 advances, we suggest examination of multiple limbic regions and their subnuclei connectivity to the cortex. 403 This may reveal more precise and nuanced dynamics between the subcortex and cortex underlie previously 404 theorised global patterns. For example, recent investigations have demonstrated spatial specificity of 405 entropic activity and thalamic connectivity associated with psychedelic subjective effects (Gaddis et al., 406 2022). Along these lines, the amygdala is composed of many subnuclei. Its small size, anatomical variability 407 and position deep within the brain presents challenges for noise-to-signal ratio and spatial location in group 408 fMRI analysis, which future imaging and research methods may overcome. Finally, increased excitation 409 among the CEN effective connectivity contrasts with previous analyses, which found a general reduction 410 in associative functional connectivity (Preller et al., 2020). While the global reduction of associative 411 connectivity may help explain experiences of ego dissolution, psychedelic experiences also contain 412 phenomenological richness (Millière, Carhart-Harris, Roseman, Trautwein, & Berkovich-Ohana, 2018). 413 Future research of CEN regions may wish to address the reliability of this effective connectivity and 414 examine links between the CEN, subjective experience, and therapeutic outcomes. Such work may benefit 415 from finer grained emotional and cognitive rating scales.

417 In sum, we demonstrated altered within-RSN effective connectivity and reduced top-down RSN-amygdala 418 effective connectivity associated with emotional and cognitive behavioural changes under psilocybin. The 419 functional significance of these changes to perceptual processes and psychopathology may be reduced 420 cognitive control and increased flexibility of these networks and the attenuated modulation of the amygdala 421 under the acute effects of psilocybin. These changes may enable a mental workspace for therapeutic 422 emotional and cognitive change. We suggest RSN attenuation of the amygdala as a potential biomarker for 423 future clinical research investigating the neural correlates of psychedelic therapeutic efficacy. Future work 424 may also build upon our effective connectivity findings to understand how connectivity underlying emotion 425 and cognition interact with the therapeutic context to effect patterns of thought and behaviour. These lines 426 of enquiry can help discern the imperative of the psychedelic subjective experience to therapeutic outcomes 427 and bridge gaps in our understanding of the relationship between brain connectivity and behaviour.

428

429 Methods

430

#### 431 *Participants*

432 The data analysed in this paper were collected as part of a previous study (registered at ClinicalTrials.gov 433 (NCT03736980)), which is reported in (Preller et al., 2020) and was approved by the Cantonal Ethics 434 Committee of Zurich. Twenty-four subjects (12 males and 11 females; mean age = 26.3 y; range = 20-40435 y; 1 subject did not complete the study) were recruited through advertisements at universities in Zurich, 436 Switzerland. All participants were deemed healthy after screening for medical history, physical 437 examination, blood analysis, and electrocardiography. The Mini-International Neuropsychiatric Interview 438 (MINI-SCID) (Sheehan et al., 1998), the DSM-IV fourth edition self-rating questionnaire for Axis-II 439 personality disorders (SCID-II) (Fydrich, Renneberg, Schmitz, & Wittchen, 1997), and the Hopkins 440 Symptom Checklist (SCL-90-R) (Franke, 2002) were used to exclude subjects with present or previous 441 psychiatric disorders or a history of major psychiatric disorders in first-degree relatives. Participants were 442 asked to abstain from prescription and illicit drug use two weeks prior to first testing and throughout the

443 duration of the study, and abstain from alcohol use 24 hours prior to testing days. Urine tests and self-report 444 questionnaires were used to verify the absence of drug and alcohol use. Urine tests were also used to exclude 445 pregnancy. Further exclusion criteria included left-handedness, poor knowledge of the German language, 446 cardiovascular disease, history of head injury or neurological disorder, history of alcohol or illicit drug 447 dependence, MRI exclusion criteria, including claustrophobia, and previous significant adverse reactions 448 to a hallucinogenic drug. All participants provided written informed consent statements in accordance with 449 the declaration of Helsinki before participation in the study. Subjects received written and oral descriptions 450 of the study procedures, as well as details regarding the effects and possible risks of drug treatment.

451

452 Design

453 A double blind, randomised, placebo-controlled, cross-over study was performed. Testing days occurred 454 two weeks apart and participants were orally administered either psilocybin (0.2mg/kg orally) or placebo 455 (179 mg mannitol and colloidal silicon dioxide (Aerosil) 1 mg. Resting state scans (10 minutes each) were 456 taken 20, 40 and 70 minutes following administration. However, only scans at 70 minutes during the peak 457 effects were used in our analysis. Participants were asked to not engage in repetitive thoughts such as 458 counting and instructed to close their eyes during the resting state scan. Subjective experience was assessed 459 using the retrospective 5-Dimensions Altered States of Consciousness (5D-ASC) questionnaire. 460 Participants completed the 5D-ASC 360 min following psilocybin administration, see Supplementary.

461

#### 462 MRI Data Acquisition and Preprocessing

MRI data were acquired on a Philips Achieva 3T whole-body scanner. A 32-channel receive head coil and MultiTransmit parallel radio frequency transmission was used. Images were acquired using a whole-brain gradient-echo planar imaging (EPI) sequence (repetition time, 2,430 ms; echo time, 27 ms; slice thickness, 3 mm; 45 axial slices; no slice gap; field of view,  $240 \times 240$  mm<sup>2</sup>; in-plane resolution,  $3 \times 3$  mm<sup>2</sup>; sensitivityencoding reduction factor, 2.0). 265 volumes were acquired per resting state scan resulting in a scan duration of 10 mins. Additionally, two high-resolution anatomical images (voxel size,  $0.7 \times 0.7 \times 0.7$  mm<sup>3</sup>) 469 were acquired using T1-weighted and T2-weighted sequences using 3D magnetization prepared rapidacquisition gradient echo sequence (MP-RAGE) and a turbo spin-echo sequence, respectively. See 470 471 details. The acquired Supplementary for more images were analysed using SPM12 472 (https://www.fil.ion.ucl.ac.uk).

The pre-processing steps of the images consisted of slice-timing correction, realignment, spatial normalization to the standard EPI template of the Montreal Neurological Institute (MNI), and spatial smoothing using a Gaussian kernel of 6-mm full-width at half maximum. Head motion was investigated for any excessive movement. Three subjects were excluded due to head motion and one subject did not complete the scan at 70 minutes.

478

479 Independent RSN-AMG DCM models

480 To reduce model complexity and focus the interpretation of the results on the connections of interest our 481 analysis investigated independent models of amygdala effective connectivity with the DMN, CEN and SN. 482

483 *Extraction of region coordinates across subjects* 

484 Neurosynth, a large-scale automated synthesis of functional neuroimaging data, was used to identify
485 coordinates composing regions of interest (Yarkoni, Poldrack, Nichols, Van Essen, & Wager, 2011). More
486 details can be found in Supplementary Material.

487 Networks were composed of cardinal regions constituting core parts of the DMN (Andrews-Hanna,

488 Reidler, Sepulcre, Poulin, & Buckner, 2010; Dixon et al., 2017), SN and CEN. The DMN and SN

followed the selection of regions in a related investigation by Zhou and colleagues (Zhou et al., 2018) and

490 all networks were included for their role in consciousness and link to emotion (Alexander et al., 2021;

491 Borders, 2020; Underwood, Tolmeijer, Wibroe, Peters, & Mason, 2021). Associations between peak

492 coordinates and cardinal nodes of network regions of interest (ROI) were determined by expert visual

493 inspection. The MNI coordinates of the selected ROIs are listed in Table 1.

A generalized linear model (GLM) was used to regress 6 head motion parameters (3 translation and 3 rotational), white matter and cerebrospinal fluid signals from preprocessed data. One subject was excluded as no activation was found in one or more regions of interest. We also used global signal regression in our pre-processing pipeline in line with our previous work (Stoliker, Novelli, et al., 2021). The time series for each ROI was computed as the first principal component of the voxel activity within a 6 mm radius sphere centred on the ROI coordinates (as listed in Table 1).

| x y z                  |  |
|------------------------|--|
| PCC 0 -50 28 DMN       |  |
| mPFC 0 54 20 DMN       |  |
| dACC 2 28 22 SN        |  |
| 1AI -34 19 0 SN        |  |
| rAI 38 18 0 SN         |  |
| 1dPFC -46 30 32 CEN    |  |
| rdPFC 42 37 31 CEN     |  |
| 11PPC -22 -62 62 CEN   |  |
| rl PPC 19 -64 55 CEN   |  |
| IAMG -21 -5 -17 Limbic |  |
| rAMG 23 -3 -19 Limbic  |  |

500

501 Table 1 Coordinates of regions of interest. The DMN comprised of the posterior cingulate cortex (PCC) and

502 medial prefrontal cortex (mPFC); the SN comprised of the dorsal anterior cingulate cortex (dorsal ACC), left

503 and right anterior insula (IAI/rAI); and the CEN comprised the left and right dorsal lateral prefrontal cortex

504 (IdPFC/rd PFC) and the left and right lateral posterior parietal lobule (IIPPC/rIPPC).

505

506 Specification and Inversion of DCM

507 Three independent fully-connected DCM models were specified for each network and the amygdala using

508 the eleven ROIs defined in Table 4, without any exogenous inputs. The DCM for each subject was then

509 inverted using spectral DCM (Karl J. Friston, Kahan, Biswal, & Razi, 2014; Razi, Kahan, Rees, & Friston, 510 2015) to infer the effective connectivity that best explains the observed cross-spectral density for each 511 subject. This procedure was repeated for each testing condition. The DCM fit to the data using cross spectral 512 density averaged 90.9% for placebo conditions and 89.8% for psilocybin conditions.

513

### 514 Second Level Analysis Using Parametric Empirical Bayes

515 The effective connectivity inferred by spectral DCM for each subject was taken to the second (group) level 516 to test hypotheses concerning between-group effects. A general linear model (GLM) was employed to 517 decompose individual differences in effective connectivity into hypothesised group-average connection 518 strengths together with unexplained noise. Hypotheses on the group-level parameters are tested within the 519 parametric empirical Bayes (PEB) framework (K. J. Friston et al., 2016), where both the expected values 520 and the covariance of the parameters were considered. That is, precise parameter estimates influence the 521 group-level result more strongly than uncertain estimates, which are down-weighted. Bayesian model 522 reduction (BMR) is used as an efficient form of Bayesian model selection (K. J. Friston et al., 2016). Please 523 see supplementary material for further technical details about PEB.

524

#### 525 Author contributions:

- 526 Conceptualization: DS, AR, FXV
- 527 Methodology: DS, LN, AR
- 528 Investigation: DS, LN, AR
- 529 Visualization: DS, LN, AR
- 530 Supervision: AR
- 531 Writing—original draft: DS
- 532 Writing—review & editing: DS, LN, AR, GE, KP, FXV
- 533
- 534

- 535 References
- Alexander, R., Aragón, O. R., Bookwala, J., Cherbuin, N., Gatt, J. M., Kahrilas, I. J., . . . Styliadis, C.
   (2021). The neuroscience of positive emotions and affect: Implications for cultivating
   happiness and wellbeing
- 539 . Neuroscience & Biobehavioral Reviews, 121, 220-249.
   540 doi:https://doi.org/10.1016/j.neubiorev.2020.12.002
- Andrews-Hanna, J. R., Reidler, J. S., Sepulcre, J., Poulin, R., & Buckner, R. L. (2010). Functionalanatomic fractionation of the brain's default network. *Neuron, 65*(4), 550-562.
  doi:10.1016/j.neuron.2010.02.005
- Atasoy, S., Roseman, L., Kaelen, M., Kringelbach, M. L., Deco, G., & Carhart-Harris, R. L. (2017).
  Connectome-harmonic decomposition of human brain activity reveals dynamical
  repertoire re-organization under LSD. *Scientific Reports*, 7. doi:10.1038/s41598-01717546-0
- Barnett, L., Muthukumaraswamy, S. D., Carhart-Harris, R. L., & Seth, A. K. (2019). Decreased
  Directed Functional Connectivity in the Psychedelic State. *bioRxiv*, 703660.
  doi:10.1101/703660
- Barrett, F. S., Doss, M. K., Sepeda, N. D., Pekar, J. J., & Griffiths, R. R. (2020). Emotions and brain
   function are altered up to one month after a single high dose of psilocybin. *Sci Rep*,
   10(1), 2214. doi:10.1038/s41598-020-59282-y
- Bernasconi, F., Schmidt, A., Pokorny, T., Kometer, M., Seifritz, E., & Vollenweider, F. X. (2014).
  Spatiotemporal brain dynamics of emotional face processing modulations induced by
  the serotonin 1A/2A receptor agonist psilocybin. *Cereb Cortex, 24*(12), 3221-3231.
  doi:10.1093/cercor/bht178
- Bonnet, L., Comte, A., Tatu, L., Millot, J.-I., Moulin, T., & Medeiros de Bustos, E. (2015). The role
  of the amygdala in the perception of positive emotions: an "intensity detector". *Frontiers in Behavioral Neuroscience, 9*(178). doi:10.3389/fnbeh.2015.00178
- Borders, A. (2020). Chapter 9 Rumination, cognition, and the brain. In A. Borders (Ed.),
   *Rumination and Related Constructs* (pp. 279-311): Academic Press.
- Brewer, J. A., Garrison, K. A., & Whitfield-Gabrieli, S. (2013). What about the "Self" is Processed
  in the Posterior Cingulate Cortex? *Front Hum Neurosci, 7*, 647.
  doi:10.3389/fnhum.2013.00647
- Brühl, A. B., Rufer, M., Kaffenberger, T., Baur, V., & Herwig, U. (2014). Neural circuits associated
  with positive and negative self-appraisal. *Neuroscience*, *265*, 48-59.
  doi:10.1016/j.neuroscience.2014.01.053
- Carhart-Harris, R., Kaelen, M., & Nutt, D. (2014). How do hallucinogens work on the brain?
   *Psychologist, 27*(9), 662-665. Retrieved from <Go to ISI>://WOS:000341172000027
- 571 Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., ... Nutt,
  572 D. J. (2018). Psilocybin with psychological support for treatment-resistant depression:
  573 six-month follow-up. *Psychopharmacology*, *235*(2), 399-408. doi:10.1007/s00213-017574 4771-x

# 575 Carhart-Harris, R. L., & Friston, K. J. (2019). REBUS and the Anarchic Brain: Toward a Unified 576 Model of the Brain Action of Psychedelics. *Pharmacological Reviews*, 71(3), 316-344. 577 doi:10.1124/pr.118.017160

- 578Carhart-Harris, R. L., & Nutt, D. J. (2017). Serotonin and brain function: a tale of two receptors.579Journal of Psychopharmacology, 31(9), 1091-1120. doi:10.1177/0269881117725915
- Davis, A. K., Barrett, F. S., & Griffiths, R. R. (2020). Psychological flexibility mediates the relations
   between acute psychedelic effects and subjective decreases in depression and anxiety. J
   *Contextual Behav Sci, 15,* 39-45. doi:10.1016/j.jcbs.2019.11.004
- Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., ...
   Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive
   Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 78(5), 481-489.
- 586 doi:10.1001/jamapsychiatry.2020.3285
- 587 Dixon, M. L., Andrews-Hanna, J. R., Spreng, R. N., Irving, Z. C., Mills, C., Girn, M., & Christoff, K.
   588 (2017). Interactions between the default network and dorsal attention network vary
   589 across default subsystems, time, and cognitive states. *NeuroImage*, 147, 632-649.
   590 doi:10.1016/j.neuroimage.2016.12.073
- Doss, M. K., Považan, M., Rosenberg, M. D., Sepeda, N. D., Davis, A. K., Finan, P. H., . . . Barrett,
   F. S. (2021). Psilocybin therapy increases cognitive and neural flexibility in patients with
   major depressive disorder. *Translational psychiatry*, *11*(1), 574. doi:10.1038/s41398 021-01706-y
- 595 Duerler, P., Vollenweider, F. X., & Preller, K. H. (2022). A neurobiological perspective on social
   596 influence: Serotonin and social adaptation. *J Neurochem*, *162*(1), 60-79.
   597 doi:10.1111/jnc.15607
- 598 Etkin, A., Egner, T., Peraza, D. M., Kandel, E. R., & Hirsch, J. (2006). Resolving Emotional Conflict:
  599 A Role for the Rostral Anterior Cingulate Cortex in Modulating Activity in the Amygdala.
  600 Neuron, 51(6), 871-882. doi:<u>https://doi.org/10.1016/j.neuron.2006.07.029</u>
- Fox, M. D., Snyder, A. Z., Vincent, J. L., Corbetta, M., Van Essen, D. C., & Raichle, M. E. (2005).
   The human brain is intrinsically organized into dynamic, anticorrelated functional
   networks. *Proceedings of the National Academy of Sciences of the United States of America*, 102(27), 9673. doi:10.1073/pnas.0504136102
- 605Franke, G. (2002). Die Symptom-Checkliste von Derogatis (SCL-90-R) Deutsche Version -606Manual.
- Friston, K. J., Kahan, J., Biswal, B., & Razi, A. (2014). A DCM for resting state fMRI. *NeuroImage*,
  94, 396-407. doi:<u>https://doi.org/10.1016/j.neuroimage.2013.12.009</u>
- Friston, K. J., Litvak, V., Oswal, A., Razi, A., Stephan, K. E., van Wijk, B. C. M., . . . Zeidman, P.
  (2016). Bayesian model reduction and empirical Bayes for group (DCM) studies. *NeuroImage*, *128*, 413-431. doi:10.1016/j.neuroimage.2015.11.015
- Fydrich, T., Renneberg, B., Schmitz, B., & Wittchen, H. U. (1997). SKID II. Strukturiertes Klinisches
   Interview für DSM-IV, Achse II: Persönlichkeitsstörungen. Interviewheft. Eine
- 614 *deutschspeachige, erw. Bearb. d. amerikanischen Originalversion d. SKID-II von: M.B.*
- 615 First, R.L. Spitzer, M. Gibbon, J.B.W. Williams, L. Benjamin, (Version 3/96).
- Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., . .
   Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in
   depression and anxiety in patients with life-threatening cancer: A randomized double-
- 619 blind trial. *Journal of Psychopharmacology, 30*(12), 1181-1197.
- 620 doi:10.1177/0269881116675513

- Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011).
  Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related
  effects. *Psychopharmacology*, *218*(4), 649-665. doi:10.1007/s00213-011-2358-5
  Herwig, U., Baumgartner, T., Kaffenberger, T., Brühl, A., Kottlow, M., Schreiter-Gasser, U., . . .
  Rufer, M. (2007). Modulation of anticipatory emotion and perception processing by
- 626 cognitive control. *NeuroImage*, *37*(2), 652-662. doi:10.1016/j.neuroimage.2007.05.023
- Herwig, U., Kaffenberger, T., Jäncke, L., & Brühl, A. B. (2010). Self-related awareness and
  emotion regulation. *NeuroImage*, *50*(2), 734-741.

629 doi:10.1016/j.neuroimage.2009.12.089

- Herwig, U., Lutz, J., Scherpiet, S., Scheerer, H., Kohlberg, J., Opialla, S., . . . Brühl, A. B. (2019).
   Training emotion regulation through real-time fMRI neurofeedback of amygdala activity.
   *NeuroImage*, 184, 687-696. doi:10.1016/j.neuroimage.2018.09.068
- Hirschfeld, T., & Schmidt, T. T. (2020). How does it feel to be on psilocybin? Dose-response
  relationships of subjective experiences in humans. *bioRxiv*, 2020.2006.2009.142802.
  doi:10.1101/2020.06.09.142802
- Jamieson, A. J., Harrison, B. J., Razi, A., & Davey, C. G. (2022). Rostral anterior cingulate network
  effective connectivity in depressed adolescents and associations with treatment
  response in a randomized controlled trial. *Neuropsychopharmacology*, 47(6), 1240-1248.
  doi:10.1038/s41386-021-01214-z
- Johnson, M., Richards, W., & Griffiths, R. (2008). Human hallucinogen research: guidelines for
  safety. In (Vol. 22, pp. 603-620). London, England.
- Kandilarova, S., Stoyanov, D., Kostianev, S., & Specht, K. (2018). Altered Resting State Effective
  Connectivity of Anterior Insula in Depression. *Frontiers in Psychiatry*, *9*.
  doi:10.3389/fpsyt.2018.00083
- Kapur, S. (2003). Psychosis as a State of Aberrant Salience: A Framework Linking Biology,
   Phenomenology, and Pharmacology in Schizophrenia. *American Journal of Psychiatry*,
   160(1), 13-23. doi:10.1176/appi.ajp.160.1.13
- Kometer, M., Schmidt, A., Bachmann, R., Studerus, E., Seifritz, E., & Vollenweider, F. X. (2012).
   Psilocybin biases facial recognition, goal-directed behavior, and mood state toward
   positive relative to negative emotions through different serotonergic subreceptors. *Biol Psychiatry*, 72(11), 898-906. doi:10.1016/j.biopsych.2012.04.005
- Kraehenmann, R., Preller, K. H., Scheidegger, M., Pokorny, T., Bosch, O. G., Seifritz, E., &
  Vollenweider, F. X. (2015). Psilocybin-Induced Decrease in Amygdala Reactivity
  Correlates with Enhanced Positive Mood in Healthy Volunteers. *Biological Psychiatry*,
  78(8), 572-581. doi:10.1016/j.biopsych.2014.04.010
- Lebedev, A. V., Lövdén, M., Rosenthal, G., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. (2015).
  Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin. *Human Brain Mapping*, *36*(8), 3137-3153. doi:10.1002/hbm.22833
- Luppi, A. I., Carhart-Harris, R. L., Roseman, L., Pappas, I., Menon, D. K., & Stamatakis, E. A.
  (2021). LSD alters dynamic integration and segregation in the human brain.
- 661 *NeuroImage*, 227, 117653. doi:https://doi.org/10.1016/j.neuroimage.2020.117653
- 662 Malinowski, P. (2013). Neural mechanisms of attentional control in mindfulness meditation.
- 663 *Front Neurosci, 7*, 8. doi:10.3389/fnins.2013.00008

664 Matias, S., Lottem, E., Dugué, G. P., & Mainen, Z. F. (2017). Activity patterns of serotonin 665 neurons underlying cognitive flexibility. eLife, 6, e20552. doi:10.7554/eLife.20552 666 McRae, K., Misra, S., Prasad, A. K., Pereira, S. C., & Gross, J. J. (2012). Bottom-up and top-down 667 emotion generation: implications for emotion regulation. Social cognitive and affective 668 neuroscience, 7(3), 253-262. doi:10.1093/scan/nsg103 Millière, R., Carhart-Harris, R. L., Roseman, L., Trautwein, F.-M., & Berkovich-Ohana, A. (2018). 669 670 Psychedelics, Meditation, and Self-Consciousness. Frontiers in Psychology, 9(1475). 671 doi:10.3389/fpsyg.2018.01475 672 Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J., Brookes, M. J., Williams, T. M., 673 Errtizoe, D., . . . Nutt, D. J. (2013). Broadband Cortical Desynchronization Underlies the 674 Human Psychedelic State. The Journal of Neuroscience, 33(38), 15171-15183. 675 doi:10.1523/jneurosci.2063-13.2013 676 Northoff, G. (2007). Psychopathology and pathophysiology of the self in depression -677 neuropsychiatric hypothesis. J Affect Disord, 104(1-3), 1-14. 678 doi:10.1016/j.jad.2007.02.012 679 Nutt, D., & Carhart-Harris, R. (2020). The Current Status of Psychedelics in Psychiatry. JAMA 680 *Psychiatry*. doi:10.1001/jamapsychiatry.2020.2171 681 Ochsner, K. N., Ray, R. R., Hughes, B., McRae, K., Cooper, J. C., Weber, J., . . . Gross, J. J. (2009). 682 Bottom-up and top-down processes in emotion generation: common and distinct neural 683 mechanisms. Psychol Sci, 20(11), 1322-1331. doi:10.1111/j.1467-9280.2009.02459.x 684 Park, J., Wood, J., Bondi, C., Del Arco, A., & Moghaddam, B. (2016). Anxiety Evokes 685 Hypofrontality and Disrupts Rule-Relevant Encoding by Dorsomedial Prefrontal Cortex 686 Neurons. The Journal of Neuroscience, 36(11), 3322-3335. doi:10.1523/jneurosci.4250-687 15.2016 688 Paulesu, E., Sambugaro, E., Torti, T., Danelli, L., Ferri, F., Scialfa, G., . . . Sassaroli, S. (2010). 689 Neural correlates of worry in generalized anxiety disorder and in normal controls: a 690 functional MRI study. Psychol Med, 40(1), 117-124. doi:10.1017/s0033291709005649 691 Paulus, M. (2006). An Insular View of Anxiety. Biol. Psychiatry, 60, 383-387. 692 doi:10.1016/j.biopsych.2006.03.042 693 Pokorny, T., Preller, K. H., Kometer, M., Dziobek, I., & Vollenweider, F. X. (2017). Effect of 694 Psilocybin on Empathy and Moral Decision-Making. International Journal of 695 *Neuropsychopharmacology*, *20*(9), 747-757. doi:10.1093/ijnp/pyx047 696 Preller, K. H., Burt, J. B., Ji, J. L., Schleifer, C. H., Adkinson, B. D., Stämpfli, P., . . . Anticevic, A. 697 (2018). Changes in global and thalamic brain connectivity in LSD-induced altered states 698 of consciousness are attributable to the 5-HT2A receptor. *eLife*, 7, e35082. 699 doi:10.7554/eLife.35082 700 Preller, K. H., Duerler, P., Burt, J. B., Ji, J. L., Adkinson, B., Stämpfli, P., . . . Vollenweider, F. X. 701 (2020). Psilocybin Induces Time-Dependent Changes in Global Functional Connectivity. 702 *Biological Psychiatry, 88*(2), 197-207. 703 doi:https://doi.org/10.1016/j.biopsych.2019.12.027 704 Preller, K. H., Herdener, M., Pokorny, T., Planzer, A., Kraehenmann, R., Stampfli, P., . . . 705 Vollenweider, F. X. (2017). The Fabric of Meaning and Subjective Effects in LSD-Induced 706 States Depend on Serotonin 2A Receptor Activation. Curr Biol, 27(3), 451-457. 707 doi:10.1016/j.cub.2016.12.030

708 Preller, K. H., Pokorny, T., Kraehenmann, R., Scheidegger, M., Dziobek, I., Staempfli, P., & 709 Vollenweider, F. X. (2015). The 5-HT2A/1A agonist psilocybin reduces social pain and 710 enhances empathy in healthy volunteers. European Neuropsychopharmacology, 25, 711 S301-S301. doi:10.1016/s0924-977x(15)30364-3 712 Preller, K. H., Razi, A., Zeidman, P., Stämpfli, P., Friston, K. J., & Vollenweider, F. X. (2019). 713 Effective connectivity changes in LSD-induced altered states of consciousness in 714 humans. Proceedings of the National Academy of Sciences, 116(7), 2743-2748. 715 doi:10.1073/pnas.1815129116 716 Qin, P., & Northoff, G. (2011). How is our self related to midline regions and the default-mode 717 network? NeuroImage, 57(3), 1221-1233. doi:10.1016/j.neuroimage.2011.05.028 718 Raichle, M. E. (2015). The brain's default mode network. Annu Rev Neurosci, 38, 433-447. 719 doi:10.1146/annurev-neuro-071013-014030 720 Razi, A., Kahan, J., Rees, G., & Friston, K. J. (2015). Construct validation of a DCM for resting 721 state fMRI. NeuroImage, 106, 1-14. 722 doi:https://doi.org/10.1016/j.neuroimage.2014.11.027 723 Roseman, L., Demetriou, L., Wall, M. B., Nutt, D. J., & Carhart-Harris, R. L. (2018). Increased 724 amygdala responses to emotional faces after psilocybin for treatment-resistant 725 depression. Neuropharmacology, 142, 263-269. 726 doi:https://doi.org/10.1016/j.neuropharm.2017.12.041 727 Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018). Quality of Acute Psychedelic Experience 728 Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. Frontiers 729 in Pharmacology, 8, 974. doi:10.3389/fphar.2017.00974 730 Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., . . . Schmidt, B. L. (2016). 731 Rapid and sustained symptom reduction following psilocybin treatment for anxiety and 732 depression in patients with life-threatening cancer: a randomized controlled trial. 733 *Journal of Psychopharmacology, 30*(12), 1165-1180. doi:10.1177/0269881116675512 734 Rotge, J. Y., Lemogne, C., Hinfray, S., Huguet, P., Grynszpan, O., Tartour, E., . . . Fossati, P. 735 (2015). A meta-analysis of the anterior cingulate contribution to social pain. Social 736 cognitive and affective neuroscience, 10(1), 19-27. doi:10.1093/scan/nsu110 737 Saulin, A., Savli, M., & Lanzenberger, R. (2012). Serotonin and molecular neuroimaging in 738 humans using PET. Amino Acids, 42(6), 2039-2057. doi:10.1007/s00726-011-1078-9 739 Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., . . . Dunbar, G. C. 740 (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development 741 and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J 742 Clin Psychiatry, 59 Suppl 20, 22-33; quiz 34-57. 743 Smigielski, L., Kometer, M., Scheidegger, M., Stress, C., Preller, K. H., Koenig, T., & Vollenweider, 744 F. X. (2020). P300-mediated modulations in self-other processing under psychedelic 745 psilocybin are related to connectedness and changed meaning: A window into the self-746 other overlap. Hum Brain Mapp, 41(17), 4982-4996. doi:10.1002/hbm.25174 747 Stoliker, D., Egan, G., Friston, K., & Razi, A. (2021). Neural Mechanisms and Psychology of 748 Psychedelic Ego Dissolution. In: PsyArXiv. 749 Stoliker, D., Egan, G. F., Friston, K. J., & Razi, A. (2022). Neural Mechanisms and Psychology of 750 Psychedelic Ego Dissolution. *Pharmacological Reviews*, 74(4), 874. 751 doi:10.1124/pharmrev.121.000508

752 Stoliker, D., Egan, G. F., & Razi, A. (2022). Reduced Precision Underwrites Ego Dissolution and 753 Therapeutic Outcomes Under Psychedelics. Frontiers in Neuroscience, 16. 754 doi:10.3389/fnins.2022.827400 755 Stoliker, D., Novelli, L., Vollenweider, F. X., Egan, G. F., Preller, K. H., & Razi, A. (2021). Effective 756 connectivity of LSD-induced ego dissolution. medRxiv, 2021.2012.2028.21268391. 757 doi:10.1101/2021.12.28.21268391 758 Stoliker, D., Novelli, L., Vollenweider, F. X., Egan, G. F., Preller, K. H., & Razi, A. (2022). Effective 759 connectivity of functionally anticorrelated networks under LSD. Biological Psychiatry. doi:10.1016/j.biopsych.2022.07.013 760 761 Studerus, E., Gamma, A., Kometer, M., & Vollenweider, F. X. (2012). Prediction of Psilocybin 762 Response in Healthy Volunteers. Plos One, 7(2). doi:10.1371/journal.pone.0030800 763 Studerus, E., Gamma, A., & Vollenweider, F. X. (2010). Psychometric evaluation of the altered 764 states of consciousness rating scale (OAV). Plos One, 5(8), e12412-e12412. 765 doi:10.1371/journal.pone.0012412 766 Swanson, L. R. (2018). Unifying Theories of Psychedelic Drug Effects. Frontiers in Pharmacology, 767 *9*(172). doi:10.3389/fphar.2018.00172 768 Tagliazucchi, E., Carhart-Harris, R., Leech, R., Nutt, D., & Chialvo, D. R. (2014). Enhanced repertoire of brain dynamical states during the psychedelic experience. Human Brain 769 770 *Mapping*, *35*(11), 5442-5456. doi:10.1002/hbm.22562 771 Tagliazucchi, E., Roseman, L., Kaelen, M., Orban, C., Muthukumaraswamy, S. D., Murphy, K., . . . 772 Carhart-Harris, R. (2016). Increased Global Functional Connectivity Correlates with LSD-773 Induced Ego Dissolution. Current biology: CB, 26(8), 1043-1050. 774 doi:10.1016/j.cub.2016.02.010 775 Terasawa, Y., Shibata, M., Moriguchi, Y., & Umeda, S. (2013). Anterior insular cortex mediates 776 bodily sensibility and social anxiety. Social cognitive and affective neuroscience, 8(3), 777 259-266. doi:10.1093/scan/nss108 778 Underwood, R., Tolmeijer, E., Wibroe, J., Peters, E., & Mason, L. (2021). Networks underpinning 779 emotion: A systematic review and synthesis of functional and effective connectivity. 780 NeuroImage, 243, 118486. doi:10.1016/j.neuroimage.2021.118486 781 Vollenweider, F. X., Leenders, K. L., Scharfetter, C., Maguire, P., Stadelmann, O., & Angst, J. 782 (1997). Positron emission tomography and fluorodeoxyglucose studies of metabolic 783 hyperfrontality and psychopathology in the psilocybin model of psychosis. 784 Neuropsychopharmacology, 16(5), 357-372. doi:10.1016/s0893-133x(96)00246-1 785 Vollenweider, F. X., & Preller, K. H. (2020). Psychedelic drugs: neurobiology and potential for 786 treatment of psychiatric disorders. Nature Reviews Neuroscience, 21(11), 611-624. 787 doi:10.1038/s41583-020-0367-2 788 Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Babler, A., Vogel, H., & Hell, D. 789 (1998). Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 790 agonist action. Neuroreport, 9(17), 3897-3902. doi:10.1097/00001756-199812010-791 00024 792 Watts, R., Day, C., Krzanowski, J., Nutt, D., & Carhart-Harris, R. (2017). Patients' Accounts of 793 Increased "Connectedness" and "Acceptance" After Psilocybin for Treatment-Resistant 794 Depression. Journal of Humanistic Psychology, 57(5), 520-564. 795 doi:10.1177/0022167817709585

796 Watts, R., Kettner, H., Geerts, D., Gandy, S., Kartner, L., Mertens, L., . . . Roseman, L. (2022). The 797 Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, 798 others, and world. Psychopharmacology. doi:10.1007/s00213-022-06187-5 799 Watts, R., & Luoma, J. B. (2020). The use of the psychological flexibility model to support 800 psychedelic assisted therapy. Journal of Contextual Behavioral Science, 15, 92-102. 801 doi:https://doi.org/10.1016/j.jcbs.2019.12.004 802 Wiebking, C., de Greck, M., Duncan, N. W., Tempelmann, C., Bajbouj, M., & Northoff, G. (2015). 803 Interoception in insula subregions as a possible state marker for depression—an 804 exploratory fMRI study investigating healthy, depressed and remitted participants. 805 Frontiers in Behavioral Neuroscience, 9. doi:10.3389/fnbeh.2015.00082 806 Yarkoni, T., Poldrack, R. A., Nichols, T. E., Van Essen, D. C., & Wager, T. D. (2011). Large-scale 807 automated synthesis of human functional neuroimaging data. Nature Methods, 8(8), 808 665-670. doi:10.1038/nmeth.1635 809 Zhou, Y., Friston, K. J., Zeidman, P., Chen, J., Li, S., & Razi, A. (2018). The Hierarchical 810 Organization of the Default, Dorsal Attention and Salience Networks in Adolescents and 811 Young Adults. Cereb Cortex, 28(2), 726-737. doi:10.1093/cercor/bhx307 812